About Us

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development.

Founded in September 2015 in Irvine, California, USA, Cloudbreak Therapeutics quickly advanced our first drug candidate through lead selection, pre-clinical IND-enabling studies and successful IND submission.

After a successful EOP2 meeting with the FDA in May 2019, Cloudbreak Therapeutics will proceed with Phase III clinical trial to develop a drug candidate which is a disease modifying, first-in-class, and the first drug therapy to treat pterygium. 

Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.

The Cloudbreak Therapeutics management team has over 50 years of combined experience with ocular drug discovery and development. In addition, Cloudbreak Therapeutics is supported by seasoned advisers and consultants.

Management

Jinsong Ni, PhD Cloudbreak Therapeutics Founder and CEO

Jinsong Ni, Ph.D

Founder, Chief Executive Officer

Van Dinh MBA Cloudbreak Therapeutics Co-Founder and COO

Van Dinh, MBA

Co-founder, Chief Operating Officer

Rong Yang, PhD Cloudbreak Therapeutics Chief Scientific Officer

Rong Yang, Ph.D

Chief Scientific Officer

Jinsong Ni, Ph.D

Founder, Chief Executive Officer

Dr. Jinsong Ni has over twenty years of pharmaceutical industry and academic research experience in drug discovery and drug development.

Prior to founding Cloudbreak Therapeutics, Dr. Ni was Scientific Director at Allergan for 15 years and Senior Scientist at Wyeth/Pfizer for 3 years. During his tenures at Allergan and Wyeth/Pfizer, Dr. Ni has been:

Member of project teams for the successful launch of many ocular and dermal products, including AlphaganP®, Combigan®, Lumigan®, Tazorac® and Ozurdex®
Member of scientific teams for marketing support of Lumigan®, Allergan P® and Ozurdex®.

Member of scientific teams for the successful legal defense of billion dollar franchise products Lumigan® and Restasis® at Allergan and multi-billion dollar franchise product Premarin® at Wyeth

Dr. Ni has served as non-clinical subteam lead and compound manager to advance numerous drug candidates to various development stages including IND and NDA submission for small and large molecule drugs across multiple therapeutic areas including CNS (neuropathic pain), ophthalmology (glaucoma, ocular surface disease and retinal disease) and dermatology (actinic keratosis, acne, rosacea), womens’ health, oncology and infectious disease.

Dr. Ni obtained his B.Sc. from Nanjing University, M.Sc. from Brock University, Ph.D. from University of Toronto and performed his Post-doctoral fellowship at the University of Utah.

Van Dinh, MBA

Co-founder, Chief Operating Officer

Van Dinh is the co-founder and Chief Operating Officer of Cloudbreak Therapeutics. Mr. Dinh has over twenty years of experience in the pharmaceutical industry.

He has worked in various scientific disciplines such as pharmacokinetics, toxicology, pharmaceutical development, and analytical sciences. Through these different disciplines, he has gained a vast amount of experience in the drug development processes. During his 18 years with Allergan, he was involved in many drug development projects and helped to bring these projects to successful commercial approvals such as Lumigan®, Combigan®, Acuvail®, Zymaxid®, Tazorac®, Ozudex®, Alphagan P®, Restasis®, Latisse®, and Lastacaft®. While at Allergan he managed departments such as In Vivo Science, Scientific Operations and Formulations and Analytical Sciences.

Mr. Dinh obtained his Master of Business Administration degree from Webster University and his Bachelor’s degree in Chemistry from the University of California, Irvine.

Rong Yang, Ph.D

Chief Scientific Officer

Dr. Yang joined Cloudbreak Therapeutics in May, 2016. He serves as Chief Scientific Officer of the company. Prior to joining Cloudbreak Therapeutics, Dr. Yang had 16 years of drug discovery and development experience with expertise in pharmacology.

Dr. Yang worked in the fields of ophthalmology, dermatology, and neurosciences at the specialty pharmaceutical company Allergan. During this time, he led multidisciplinary teams and collaborated with other companies. 

Dr. Yang participated in several drug development projects including the Taz microsphere project (reached phase I), the PDE project (reached early development) and the GABA modulator project (reached phase II).

Dr. Yang holds a Ph.D. in biochemistry from the University of Wisconsin-Madison, a B.S.c in biology from Peking University, and performed his post-doctoral fellowship at the University of California, Los Angeles Cancer Center.

Scott Whitcup, MD

Dr. Scott Whitcup is the Founder and CEO of Akrivista and Whitecap Biosciences, two companies focused on developing new therapies in ophthalmology and dermatology.

Previously, Dr. Whitcup was the Executive Vice President, Research and Development and Chief Scientific Officer at Allergan where he lead an organization focused on therapeutic areas including ophthalmology, CNS, urology, dermatology, medical aesthetics, anti-infectives, and surgical obesity. 

Before Allergan, Dr. Whitcup was the Clinical Director at The National Eye Institute at the National Institutes of Health (NIH), where he led the intramural clinical research program.

Dr. Whitcup has 17 issued and 20 pending US patents. He is a Diplomate of both the American Board of Internal Medicine and the American Board of Ophthalmology, a licensed M.D. in CA, and is on the Clinical Faculty of the Department of Ophthalmology at the Jules Stein Eye Institute, David Geffen School of Medicine. Dr. Whitcup serves on the Board of Semnur Pharmaceuticals, Menlo Therapeutics and NightstaRx. He served on the Board of Avanir Pharmaceuticals, and Questcor Pharmaceuticals.

Dr. Whitcup has a B.A. in Neurobiology and Behavior from Cornell University and an M.D. from Cornell University Medical College. He completed his residency in Internal Medicine at the UCLA Medical Center, his residency in Ophthalmology at Harvard Medical School-Massachusetts Eye & Ear Infirmary, and a fellowship in Uveitis and Ocular Immunology at the National Eye Institute at the National Institutes of Health (NIH).

John Hovanesian, MD

Dr. John Hovanesian is a board certified ophthalmologist and a faculty member at the UCLA Jules Stein Eye Institute. He is an internationally recognized leader in the fields of corneal, cataract, refractive and laser surgery.

Dr. Hovanesian received his medical degree from the University of Michigan Medical School and completed his fellowship in ophthalmology at the Jules Stein Eye Institute at UCLA. He is currently a clinician at Harvard Eye Associates and a clinical faculty at UCLA.

Dr. Hovanesian is widely regarded as the leader in pterygium disease treatment. He is the editor of the textbook “Pterygium Techniques and Technology for Surgical Success” and lead author of 2017 Pterygium “White Paper”. He is the chairman of American Academy of Ophthalmology, Anterior Segment and an editorial board member for five other ophthalmology journals. He has been honored by the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery for his contributions to the field.

Dr. Hovanesian is also the Principal Investigator for over 16 ophthalmology clinical trials and the member of over 20 scientific and medical advisory boards.